Ireland - English - HPRA (Health Products Regulatory Authority)

auden mckenzie (pharma division) ltd - mometasone furoate - cream - 0.1 percent weight/weight - corticosteroids, potent (group iii); mometasone

Ireland - English - HPRA (Health Products Regulatory Authority)

auden mckenzie (pharma division) ltd - mometasone furoate - ointment - 0.1 percent weight/weight - corticosteroids, potent (group iii); mometasone

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 100 ug - asmanex® hfa is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. important limitations of use - asmanex hfa is not indicated for the relief of acute bronchospasm. asmanex hfa is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. asmanex hfa is contraindicated in patients with known hypersensitivity to mometasone furoate or any of the ingredients in asmanex hfa [see warnings and precautions (5.8)] . risk summary there are no randomized clinical studies of asmanex hfa in pregnant women. there are clinical considerations with the use of asmanex hfa in pregnant women [see clinical considerations] . in animal reproduction studies with pregnant mice, rats, or rabbits, mometasone furoate caused increased fetal malformations and decreased fetal survival and growth following administration of doses that produced exposures approximately 1/3 to 8 times the maximum recommend

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 g - elocon cream 0.1% is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. elocon (mometasone furoate cream) cream 0.1% may be used in pediatric patients 2 years of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established (see precautions – pediatric use section). since safety and efficacy of elocon cream 0.1% have not been established in pediatric patients below 2 years of age, its use in this age group is not recommended. elocon cream 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 g - elocon® cream is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. elocon cream is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, elocon cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossific

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 ml - elocon® lotion is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. elocon lotion is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. there are no adequate and well-controlled studies in pregnant women. therefore, elocon lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. mometasone furoate also caused d

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 g - elocon® ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. elocon ointment is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, elocon ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8), formoterol fumarate (unii: w34shf8j2k) (formoterol - unii:5zz84gcw8b) - mometasone furoate 100 ug - dulera is indicated for the twice-daily treatment of asthma in patients 5 years of age and older. dulera should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use: - dulera is not indicated for the relief of acute bronchospasm. dulera is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. dulera is contraindicated in patients with known hypersensitivity to mometasone furoate, formoterol fumarate, or any of the ingredients in dulera [see warnings and precautions (5.10)] . risk summary there are no randomized clinical studies of dulera, mometasone furoate, or formoterol fumarate in pregnant women. there are clinical considerations with the use of dulera in pregnant women [see clinical considerations] . animal

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 220 ug - asmanex® twisthaler® is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. important limitations of use asmanex twisthaler is not indicated for the relief of acute bronchospasm. asmanex twisthaler is not indicated in children less than 4 years of age. asmanex twisthaler therapy is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. asmanex twisthaler is contraindicated in patients with known hypersensitivity to milk proteins or any ingredients of asmanex twisthaler. [see warnings and precautions (5.3) and description (11)]. pregnancy category c: there are no adequate and well-controlled studies of asmanex twisthaler use in pregnant women. animal reproduction studies in mice, rats, and rabbits revealed evidence of teratogenicity. asthma is a serious and potentially life-threatening condition. poorly controlled asthma during pregnancy is associated with adverse outc

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - mometasone furoate, quantity: 1 mg/g - ointment - excipient ingredients: hexylene glycol; white soft paraffin; white beeswax; propylene glycol monostearate - mometasone medis ointment is indicated for short-term (up to 4 continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, such as psoriasis and atopic dermatitis.